“intercept-pharmaceuticals” Archives

in
Entry Author Date Location
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries 10/01/20 Europe
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More 09/04/20 National
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% 09/01/20 New York
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More 08/07/20 National
CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage 08/04/20 San Francisco
FDA Lifts CymaBay Drug Hold, Tests to Resume in Rare Liver Disease PBC 07/23/20 San Francisco
3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments 07/13/20 National
FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data 06/29/20 New York
Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More 05/29/20 National
Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate 11/08/19 National
Enanta Steps Forward in NASH Race, With Unclear Prospects 09/26/19 Boston
Conatus to Slash Staff, Consider Sale After NASH Trial Failures 06/25/19 San Diego
CymaBay Therapeutics Stumbles in NASH Race, Shares Fall 06/11/19 San Francisco
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More 04/12/19 National
Intercept Touts a Smaller Piece of Its NASH Trial at Liver Conference 04/11/19 New York
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More 02/22/19 National
With New Data, Intercept On Track for First-Ever Approved NASH Drug 02/19/19 New York
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Eyeing NASH, Glympse Raises $22M to Test Disease Detection Nanotech 10/09/18 Boston
Viking Liver Drug Shows Promise for NASH, Shares Soar on Study Data 09/18/18 San Diego
Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen 06/25/18 Boston
15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) 12/04/17 National
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More 02/17/17 National
With $20M, UCSD Spinout Jecure To Press New Attack On NASH 02/15/17 San Diego
Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More 10/14/16 National
With Tobira Deal, Allergan Keeps Shopping For “Questionable” Assets 09/20/16 San Francisco
With First Drug Approved, Intercept Taps Kapadia As New CFO 06/09/16 New York
Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes 06/03/16 National
Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease 05/28/16 New York
East Coast Biotech Roundup: PfizerGan, Nimbus, Intercept, Tesaro & More 04/08/16 Boston
Page 1 of 2 next page »